ArticleBMC cancer2014
Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.
Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Trial
- Validation and prognostic utility of the mSMART 4.0 risk stratification system in Chinese patients with multiple myeloma.BMC cancer · 2026Article
- Establishment of prognostic nomogram in cervical cancer with hepatitis B virus infection: a retrospective study.Frontiers in oncology · 2026Article
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.Cancers · 2024Article
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.Blood cancer journal · 2024Article
- Serum aspartate aminotransferase, a novel potential biomarker of prognosis in extranodal natural killer/T cell lymphoma, nasal type.Cancer biomarkers : section A of Disease markers · 2024Article
- Preclinical Evaluation of aPharmaceutics · 2023Article
- The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma.Current oncology (Toronto, Ont.) · 2023Article
- Pretreatment Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase Predict the Prognosis of Metastatic Cervical Cancer Treated with Combination Immunotherapy.Journal of oncology · 2022Article
- LDH, CRP and ALB predict nucleic acid turn negative within 14 days in symptomatic patients with COVID-19.Scottish medical journal · 2021Article
- Prognostic Significance of the Lung Immune Prognostic Index in Patients with Resected Esophageal Squamous Cell Carcinoma.Cancer management and research · 2021Article
- Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma.BMC cancer · 2019Article
- Article
- Article
- Identification and expression of MMSA-8, and its clinical significance in multiple myeloma.Oncology reports · 2017Article
- Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study.Cancer management and research · 2017Article
- MMSA-1 expression pattern in multiple myeloma and its clinical significance.Clinical and experimental medicine · 2016Article
- Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer.Cancer medicine · 2016Article
- Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms.Oncotarget · 2016Article
- Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBortezomib offers a novel approach to the treatment of multiple myeloma producing rapid control. The aim of this study was to investigate the outcomes of bortezomib and dexamethasone-treated patients with multiple myeloma.
methodsWe conducted a retrospective study of 44 consecutively-treated multiple myeloma patients with bortezomib (1.3 mg/m(2) on days 1, 4, 8, and 11 of a 21-day cycle or 1.3 mg/m(2) intravenously 1, 8, 15, and 22 of every 35-day cycle) and dexamethasone.
resultsThe median time to progression, progression free survival time, and overall survival time in the treatment groups was 14.9, 14.9, and 38.3 months, respectively. The present study also suggests the possibility that the prognosis of patients with high levels of AST and LDH might be worse.
conclusionsOur results indicate that the treatment of multiple myeloma with bortezomib and dexamethasone is feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.